Argenx Se (ARGX) Liabilities and Shareholders Equity (2015 - 2025)
Argenx Se (ARGX) posted Liabilities and Shareholders Equity of $8.7 billion for Q4 2025, up 120903.23% on a QoQ basis from $7.2 million in Q2 2025, and up 39.99% year-over-year from $6.2 billion in Q4 2024.
Argenx Se (ARGX) Liabilities and Shareholders Equity (2015 - 2025) Analysis & Trends
Argenx Se's Liabilities and Shareholders Equity history runs 11 years deep, the most recent figure standing at $8.7 billion for Q4 2025.
- Quarterly Liabilities and Shareholders Equity rose 39.99% year-over-year to $8.7 billion in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $8.7 billion (down 20.99% YoY) and the FY2025 annual result came in at $8.7 billion, up 39.99% from the prior year.
- Liabilities and Shareholders Equity was $8.7 billion for Q4 2025 at Argenx Se, up from $7.2 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $8.7 billion in Q4 2025 and bottomed at $7.2 million in Q2 2025.
- A 5-year average of $4.0 billion and a median of $3.2 billion in 2021 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity surged 50.18% — and 2025, when it tumbled 99.85%.
- Argenx Se's Liabilities and Shareholders Equity stood at $2.9 billion in 2021, then advanced by 9.96% to $3.1 billion in 2022, then jumped by 44.93% to $4.5 billion in 2023, then surged by 36.55% to $6.2 billion in 2024, then soared by 39.99% to $8.7 billion in 2025.
- Business Quant data shows ARGX's Liabilities and Shareholders Equity at $8.7 billion in Q4 2025, $7.2 million in Q2 2025, and $6.2 billion in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 78.88 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 33.89 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 8.55 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 2.25 Bn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 5.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8.68 Bn |
| Jun 30, 2025 | 7.18 Mn |
| Dec 31, 2024 | 6.20 Bn |
| Jun 30, 2024 | 4.80 Bn |
| Dec 31, 2023 | 4.54 Bn |
| Jun 30, 2023 | 3.19 Bn |
| Dec 31, 2022 | 3.13 Bn |
| Jun 30, 2022 | 3.25 Bn |
| Dec 31, 2021 | 2.85 Bn |
| Jun 30, 2021 | 3.21 Bn |
| Dec 31, 2020 | 2.21 Bn |
| Jun 30, 2020 | 2.23 Bn |
| Dec 31, 2019 | 1.59 Bn |
| Jun 30, 2019 | 1.13 Bn |
| Dec 31, 2018 | 660.25 Mn |
| Jun 30, 2018 | 429.66 Mn |
| Dec 31, 2017 | 436.72 Mn |
| Jun 30, 2017 | 203.95 Mn |
| Dec 31, 2016 | 114.20 Mn |
| Dec 31, 2015 | 50.38 Mn |